Ads
related to: treatment for mycosis fungoides
Search results
Results From The WOW.Com Content Network
The most commonly recommended first-line treatment for mycosis fungoides is psoralen plus ultraviolet A (PUVA therapy). [5] PUVA is a photochemotherapy that involves topical or oral administration of the photosensitizing drug psoralen followed by skin exposure to ultraviolet radiation. [20]
PUVA (psoralen and UVA) is an ultraviolet light therapy treatment for skin diseases: vitiligo, eczema, psoriasis, graft-versus-host disease, mycosis fungoides, large plaque parapsoriasis, and cutaneous T-cell lymphoma, using the sensitizing effects of the drug psoralen.
2 Treatment. 3 See also. 4 References. 5 Further reading. 6 External links. Toggle the table of contents. Pagetoid reticulosis. ... "mycosis fungoides palmaris et ...
The US Food and Drug Administration (FDA) approved mogamulizumab in August 2018, [15] for the treatment of relapsed or refractory mycosis fungoides and Sézary disease. [8] Mogamulizumab was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma and in 2014, for relapsed or refractory CCR4 ...
Sézary disease and mycosis fungoides are cutaneous T-cell lymphomas having a primary manifestation in the skin. [5] The disease's origin is a peripheral CD4+ T-lymphocyte, [ 3 ] although rarer CD8+/CD4- cases have been observed. [ 3 ]
The presentation depends if it is mycosis fungoides or Sézary syndrome, the most common, though not the only types. Among the symptoms for the aforementioned types are: enlarged lymph nodes, an enlarged liver and spleen, and non-specific dermatitis. [1]